Search Results - "Lapthorn, Alice R" :: K.UTB vyhledávací portál

Loading…

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease

by Ilg, Marcus M, Lapthorn, Alice R, Ralph, David J, Cellek, Selim
Published in PloS one (12.12.2022)

Get full text

Journal Article

Loading…

Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility

by Ilg, Marcus M, Harding, Sophie, Lapthorn, Alice R, Kirvell, Sara, Ralph, David J, Bustin, Stephen A, Ball, Graham, Cellek, Selim
Published in Journal of sexual medicine (28.03.2024)

Get full text

Journal Article

Loading…

(109) CONFIRMING ANTI-FIBROTIC EFFECT OF TERFENADINE, EBASTINE, AND SOLIFENACIN IN IN VITRO MODELS OF PEYRONIE’S DISEASE

by Dr. Marcus M, Ilg, Dr. Alice R, Lapthorn, Prof. David J, Ralph, Prof. Selim, Cellek
Published in Journal of sexual medicine (06.07.2023)

Get full text

Journal Article

Loading…

(118) THE MECHANISM OF ACTION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN PREVENTING MYOFIBROBLAST TRANSFORMATION IN IN VITRO MODELS OF PEYRONIE’S DISEASE

by Sophie L, Harding, Dr. Marcus M, Ilg, Dr. Alice R, Lapthorn, Prof. Selim, Cellek, Prof. David J, Ralph
Published in Journal of sexual medicine (06.07.2023)

Get full text

Journal Article

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease

Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility

(109) CONFIRMING ANTI-FIBROTIC EFFECT OF TERFENADINE, EBASTINE, AND SOLIFENACIN IN IN VITRO MODELS OF PEYRONIE’S DISEASE

(118) THE MECHANISM OF ACTION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN PREVENTING MYOFIBROBLAST TRANSFORMATION IN IN VITRO MODELS OF PEYRONIE’S DISEASE

Refine Results

Format

Subject Area

Topic

Language

Year of Publication

Database